Porton’s recognition by Roche is a testament to the high-quality service and technical expertise that comes with working with a leading global end-to-end CDMO.

<December 16, 2022>

Shanghai China (December 16, 2022) - Porton Pharma Solutions (hereinafter referred to as Porton) was recently awarded as a winner of the Roche CDMO Award 2021 in recognition of significant contribution to Roche’s ATP project. This award is designated for a collaborator of the company and honors top level project performance for a CDMO in a given year, as well as compliance to strict regulatory and quality requirements. Roche is an esteemed player in the pharmaceutical industry, and Porton is proud to be the recipient of this award.

In addition to the Roche team, members of Porton in attendance at the award ceremony taking place simultaneously in Shanghai, China and Basel, Switzerland included Mr. Oliver Ju, Chairman & CEO of Porton, Mr. Yaohui Ji, General Manager of Porton’s Small Molecule Business Unit, and members of the project team.

 

Recipient of the Roche CDMO Award 2021

Dr. Thomas Osswald, head of external technical oversight at Roche, briefly illustrated the motivation of this award, reviewing the 14 years history of the Roche-Porton relationship, as well as acknowledging the development of the company and becoming a mature company over the years with expansion into Europe. Additionally, Porton’s rapid response to customer needs, high quality project management, significant flexibility, and proactive development approach were emphasized amongst other key highlights of the partnership. These are key customer values that have been and continually will be the foundation of a customer relationship with Porton.

Dr. Pavlos Kouroupis, Senior VP of Business Development in Europe and Key Account Manager for Roche, who served as the representative for Porton in the ceremony in Basel, thanked Roche for its trust and commendation and hoped the collaboration between Roche and Porton become stronger and deeper. “Roche has been a long withstanding partner of Porton, and we are proud to work with them to bring new therapies to market. Recognitions like this serve as a testament to our commitment to quality and customer service, as well as our ability to solve complex challenges as an end-to-end CDMO partner to the pharmaceutical industry.”

Porton’s strategic plans to expand into Europe are now speeding up, with the expansion of a pilot plant and manufacturing facility in Menges, Slovenia. The aim for this is to be able to cater to needs of multinational organizations in Europe, as well as provide global contingency for all of our customers. The commissioning of this site is anticipated for late Q3 of 2024.

 

Porton Shanghai Headquarters

 

Roche Basel

 

About Porton

With over 5000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions Ltd. provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.
Our Process Technology Centers and WHO/USFDA/EMA/PDMA/NMPA-inspected Manufacturing Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets, plus over 1400 highly skilled scientists and process engineers, all backed by a proven program management system dedicated to seamlessly delivering successful outcomes for your unique project requirements. 
We are committed to be the most open, innovative and reliable pharmaceutical service platform in the world and Enabling public’s early access to good medicines. We constantly strive for excellence, and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance and 

Please do not cite or reproduction without authorized by Porton.